Erlotinib plus bevacizumab combination studies

Erlotinib plus bevacizumab is a clinical guideline-recommended first-line treatment option for EGFR Mut+ NSCLC.1

Bevacizumab is an anti-VEGF monoclonal antibody that inhibits tumour growth by inhibiting new and recurrent tumour vessel growth.2

Bevacizumab also reduces tumour size by regressing existing tumour vasculature.2-4

Please click below for more information on the key clinical trials that demonstrate
erlotinib plus bevacizumab’s favourable efficacy and safety profile in the first-line treatment of EGFR Mut+ NSCLC.

BELIEF phase II trial
(European patients)
JO25567 phase II trial
(Japanese patients)
NEJ026 phase III trial
(Japanese patients)

Please note; in some countries the combination of erlotinib plus bevacizumab may not be registered or reimbursed